{"product_id":"new-drugs-plus-chemotherapy-for-plasmablastic-lymphoma-what-a-major-analysis-found","title":"New Drugs Plus Chemotherapy for Plasmablastic Lymphoma: What a Major Analysis Found","description":"\u003cp\u003eThis meta-analysis combined 12 studies and 410 patients with plasmablastic lymphoma (PBL), a rare and aggressive blood cancer. Researchers found that adding newer drugs — especially bortezomib — to standard chemotherapy improved the objective response rate (56.8% vs. 70.2%) and progression-free survival compared with traditional treatment. Overall survival and rates of serious side effects were similar between the two approaches, but the authors caution that the small sample size means the results should be interpreted carefully.\u003c\/p\u003e\n\n\u003ch1\u003eNew Drugs Plus Chemotherapy for Plasmablastic Lymphoma: What a Major Analysis Found\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#quality\"\u003eHow Study Quality Was Assessed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: Response Rates and Survival\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#adverse\"\u003eSide Effects and Safety\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#bias\"\u003ePublication Bias and Study Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#discussion\"\u003eWhat the Results Mean in Context\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#future\"\u003eEmerging Treatments and Future Directions\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Actionable Advice\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Study Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#conclusion\"\u003eConclusion\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn 410 newly diagnosed PBL patients across 12 studies, adding newer drugs — especially bortezomib — to standard chemotherapy improved objective response rate (70.2% vs. 56.8%).\u003c\/li\u003e\n\u003cli\u003eProgression-free survival was significantly better with new drug combinations (HR 2.22, P \u0026lt; 0.001), but overall survival was not significantly different (HR 1.81, P = 0.41).\u003c\/li\u003e\n\u003cli\u003eSerious side effects (grade 3–4) were similar between groups (HR 0.85, P = 0.78); adding new drugs did not increase their rate.\u003c\/li\u003e\n\u003cli\u003eThe analysis included mostly retrospective studies and only 410 patients, with high heterogeneity (I² = 95% for objective response rate), so results should be interpreted carefully.\u003c\/li\u003e\n\u003cli\u003eThe authors suggest bortezomib combined with EPOCH or CHOP, plus local radiotherapy as appropriate and ASCT for some high-risk patients, as a more appropriate option for newly diagnosed PBL.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003ePlasmablastic lymphoma (PBL) is a rare and highly aggressive type of non-Hodgkin lymphoma (a cancer of the immune system's white blood cells). PBL is known for being resistant to standard drug treatments and for having poor survival rates.\u003c\/p\u003e\n\n\u003cp\u003eCurrently, there is no standard treatment for PBL. Doctors mainly rely on medium- to high-intensity combination chemotherapy (treatment using multiple cancer-killing drugs at once). The most commonly used regimens come from treatments developed for HIV-related non-Hodgkin lymphoma.\u003c\/p\u003e\n\n\u003cp\u003eThese traditional regimens include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCHOP\u003c\/strong\u003e — cyclophosphamide, doxorubicin, vincristine, and prednisone\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEPOCH\u003c\/strong\u003e — etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ehyper-CVAD-MA\u003c\/strong\u003e — cyclophosphamide, vincristine, doxorubicin, dexamethasone, plus high-dose methotrexate and cytarabine\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCODOX-M\/IVAC\u003c\/strong\u003e — a combination regimen used in aggressive lymphomas\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe National Comprehensive Cancer Network (NCCN) Guidelines, version 2024.1, recommend using regimens stronger than CHOP for PBL. However, even with these stronger treatments, outcomes remain poor.\u003c\/p\u003e\n\n\u003cp\u003eTo improve treatment results and overcome drug resistance, researchers are urgently investigating newer drugs. These include \u003cstrong\u003ebortezomib\u003c\/strong\u003e, \u003cstrong\u003elenalidomide\u003c\/strong\u003e, and \u003cstrong\u003eixazomib\u003c\/strong\u003e. However, randomized controlled trials (the gold-standard type of clinical study) for these drugs in PBL are very limited.\u003c\/p\u003e\n\n\u003cp\u003eThis is why the authors conducted a systematic review and meta-analysis. A meta-analysis combines data from multiple studies to produce a more powerful overall result. The goal was to compare the effectiveness, survival outcomes, and safety of combining new drugs (such as bortezomib) with traditional regimens. Traditional regimens include EPOCH, CHOP-like regimens, and\/or radiation therapy. The comparison was in patients newly diagnosed with PBL.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers followed strict, internationally recognized methods for conducting a systematic review. The study was registered with PROSPERO (an international database of systematic reviews) under registration number CRD42024578897.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhich studies were included?\u003c\/strong\u003e The researchers included studies that met all of the following criteria:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eProspective randomized controlled trials (RCTs) or retrospective analyses (studies looking back at patient records) from domestic and international sources\u003c\/li\u003e\n  \u003cli\u003ePatients newly diagnosed with PBL\u003c\/li\u003e\n  \u003cli\u003eAll PBL diagnoses confirmed by histopathologic examination (microscopic tissue analysis) and immunohistochemistry (IHC) studies (tests that identify specific proteins on cells)\u003c\/li\u003e\n  \u003cli\u003eA minimum of 10 patients in the study\u003c\/li\u003e\n  \u003cli\u003eThe study reported treatment outcomes such as response rate, progression-free survival, or overall survival\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhich studies were excluded?\u003c\/strong\u003e The researchers excluded:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eArticles where the full text could not be obtained\u003c\/li\u003e\n  \u003cli\u003eLiterature reviews and conference papers\u003c\/li\u003e\n  \u003cli\u003eStudies with incomplete information for data extraction\u003c\/li\u003e\n  \u003cli\u003eStudies that had been published more than once (duplicate publications)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhere did they search?\u003c\/strong\u003e The researchers searched PubMed, Embase, Medline, Web of Science, the Cochrane Central Register of Controlled Trials, the Cochrane Library, the Science Citation Index, and conference abstracts. The search cut-off date was August 2024. Keywords included \"plasma cell lymphoma,\" \"plasmablastic lymphoma,\" \"treatment,\" and \"management.\" No language restrictions were applied.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHow was data collected?\u003c\/strong\u003e Two reviewers (Guo and Quan) independently extracted data from each included study. They collected information on the first author, publication journal, year of publication, number of patients in each group, average age, treatment regimen, effectiveness, and adverse reactions. Any disagreements were resolved through discussion or third-party evaluation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHow were patients grouped?\u003c\/strong\u003e Based on whether treatment included new drugs, patients were divided into two subgroups:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSubgroup 1:\u003c\/strong\u003e Traditional treatment versus no treatment\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSubgroup 2:\u003c\/strong\u003e Traditional treatment versus a combination of new drugs plus traditional treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhat outcomes were measured?\u003c\/strong\u003e The study tracked four main outcomes:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eObjective response rate (ORR)\u003c\/strong\u003e — the proportion of patients who achieved complete remission (CR, no detectable cancer) or partial remission (PR, significant reduction in cancer) among all patients eligible for assessment. This was evaluated using the Lugano 2014 criteria.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProgression-free survival (PFS)\u003c\/strong\u003e — the time from starting treatment to the first recurrence, progression, death, or last follow-up for any reason\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall survival (OS)\u003c\/strong\u003e — the time from starting treatment to death or last follow-up for any reason\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGrade 3 or higher adverse events (AE)\u003c\/strong\u003e — serious side effects, assessed according to the Common Terminology Criteria for Adverse Events (CTCAE)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eHow was the statistical analysis performed?\u003c\/strong\u003e The researchers used RevMan 5.4 software. When significant statistical heterogeneity existed among studies (I² \u0026gt; 50%, P \u0026lt; 0.1), they used a random-effects model. When studies were homogeneous (I² ≤ 50%, P ≥ 0.1), they used a fixed-effects model. Mean difference (MD) and its 95% confidence interval (CI) were used for quantitative data, and relative risk (RR) was used for count data. A P-value less than 0.05 indicated a statistically significant difference. Funnel plots were used to assess publication bias.\u003c\/p\u003e\n\n\u003ch2 id=\"quality\"\u003eHow Study Quality Was Assessed\u003c\/h2\u003e\n\n\u003cp\u003eTwo reviewers used the Newcastle–Ottawa Scale (NOS) to evaluate the quality of each included study. The NOS assesses three areas:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSelection of study subjects\u003c\/strong\u003e — scored 0 to 4 points\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComparability\u003c\/strong\u003e — scored 0 to 2 points\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExposure or outcome assessment\u003c\/strong\u003e — scored 0 to 3 points\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe maximum NOS score was 9 points. Studies scoring 6 or higher were considered high quality, while scores below 4 were considered low quality. The two reviewers agreed on over 80% of the quality assessment items. When they disagreed, they held discussions or consulted with experts. All included studies scored between 6 and 8 points, meaning all were classified as high-quality studies.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers also used the Cochrane bias risk assessment criteria to evaluate potential bias in the included studies.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: Response Rates and Survival\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers retrieved a total of 1,603 articles from their searches (PubMed: 664, Embase: 907, Cochrane Central Database: 20, Clinical Trials: 3, Wan Fang: 9). After removing duplicate articles, reviews, and conference abstracts, they screened titles and abstracts. Finally, they included 12 articles after reading the full text, covering a total of 410 patients with PBL.\u003c\/p\u003e\n\n\u003cp\u003eOf the 12 included studies, 11 were retrospective studies and 1 was a randomized controlled trial.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePatient groups:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSubgroup 1\u003c\/strong\u003e included 152 patients who received traditional regimens (EPOCH, CHOP-like regimens, and\/or local radiotherapy) and 30 patients in the control group who received no treatment. Patients who received only palliative (comfort-focused) care did so because of older age at diagnosis, poor performance status, co-morbidities (other health conditions), or because they could not tolerate chemotherapy. Some patients who were HIV-positive had received anti-retroviral therapy (ART) alone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSubgroup 2\u003c\/strong\u003e included 115 patients who received traditional regimens and 44 patients who received traditional regimens combined with new drugs (bortezomib, lenalidomide, or CAR-T therapy).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eObjective response rate (ORR):\u003c\/strong\u003e Among patients eligible for efficacy assessment, the ORR was higher in the combined new drug group than in the traditional treatment group. The rates were \u003cstrong\u003e56.8% (25 out of 44 patients)\u003c\/strong\u003e in the traditional treatment group versus \u003cstrong\u003e70.2% (66 out of 94 patients)\u003c\/strong\u003e in the combined new drug group. The odds ratio (OR) was 2.18, with a 95% confidence interval of 1.58 to 2.78, and P = 0.002. Because this P-value is less than 0.05, the difference was statistically significant. However, heterogeneity among study results was very high at I² = 95%, meaning the studies varied considerably in their results.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eProgression-free survival (PFS):\u003c\/strong\u003e Four studies used hazard ratios (HR) to assess OS and PFS. The progression-free survival rate was better in the combined new drug group compared with the traditional treatment group. The hazard ratio was 2.22, with a 95% confidence interval of 1.71 to 2.90, and P \u0026lt; 0.001. This result was statistically highly significant.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOverall survival (OS):\u003c\/strong\u003e There was no statistically significant difference between the two groups in overall survival. The hazard ratio was 1.81, with a 95% confidence interval of 0.44 to 7.46, and P = 0.41. Because the P-value is greater than 0.05, this difference was not statistically significant.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFollow-up and outcomes across studies:\u003c\/strong\u003e The included studies reported varying follow-up periods and outcomes:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eJorge Castillo (2008): 112 patients, 19-month follow-up, overall survival 15 months, mortality rate 29 out of 55 patients (53%)\u003c\/li\u003e\n  \u003cli\u003eYusuke Koizumi (2016): 24 patients, 15-month follow-up, PFS 13 months, OS 15 months\u003c\/li\u003e\n  \u003cli\u003eAriela Noy (2016): 12 patients, 73-week follow-up (range 40–165 weeks), OS 11.6 months (range 2–63 months)\u003c\/li\u003e\n  \u003cli\u003eBrenda Mai (2020): 21 patients, 19-month follow-up (range less than 1 to 112 months), OS 4.7 months, mortality rate 9 out of 16 patients (75%)\u003c\/li\u003e\n  \u003cli\u003eA. H. Rudresha (2020): 13 patients, 33-month follow-up, OS 9 months, mortality rate 6 out of 13 patients (46%)\u003c\/li\u003e\n  \u003cli\u003eJayachandran Perumal Kalaiyarasi (2020): 25 patients, 26.9-month follow-up (range 0.3–34.1 months), PFS 5.9 months, OS 12.4 months\u003c\/li\u003e\n  \u003cli\u003eNadine Rapiti (2022): 26 patients, 78-month follow-up, PFS 8 months (range 1–97 months), OS 16 months (range 1–111 months)\u003c\/li\u003e\n  \u003cli\u003eChristopher Dittus (2018): 8 patients, 48-month follow-up, PFS 10.8 months (range 0.73–77.8 months), OS 10.8 months (range 0.73–77.8 months)\u003c\/li\u003e\n  \u003cli\u003eFu Weijia (2020): 15 patients, 30.3-month follow-up (range 4.8–61.1 months), PFS 6.8 months (range 2.5–11.1 months), OS 17.9 months (range 5.6–30.2 months), mortality rate 8 out of 15 patients (53%)\u003c\/li\u003e\n  \u003cli\u003eRehan Jessa (2022): 42 patients, 96-month follow-up, PFS 8 months, OS 15 months\u003c\/li\u003e\n  \u003cli\u003eBrian T. Hess (2023): 80 patients, 34-month follow-up (range 1–196 months), PFS rate 72% (95% CI 62–83%), OS rate 79% (95% CI 70–89%)\u003c\/li\u003e\n  \u003cli\u003eNing Dong (2023): 32 patients, 77.6-month follow-up, PFS 6.7 months (range 3.4–8.3 months) versus not reached, OS 14.7 months (range 10.2–33.7 months) versus 89.1 months (range 56.7 months to not available)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"adverse\"\u003eSide Effects and Safety\u003c\/h2\u003e\n\n\u003cp\u003eAmong 159 patients eligible for safety assessment, there was no significant difference in grade 3–4 adverse events (serious side effects) between the two groups. The hazard ratio was 0.85, with a 95% confidence interval of 0.27 to 2.71, and P = 0.78. Because the P-value is greater than 0.05, this difference was not statistically significant.\u003c\/p\u003e\n\n\u003cp\u003eThis means that adding new drugs to traditional treatment did not increase the rate of serious side effects. The authors noted that combination treatment for PBL can cause adverse reactions such as neurotoxicity (nerve damage). However, the results of this meta-analysis are consistent with known reports about adverse reactions, and the new drugs did not increase the incidence of adverse events.\u003c\/p\u003e\n\n\u003ch2 id=\"bias\"\u003ePublication Bias and Study Limitations\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers used funnel plots to assess publication bias (the tendency for studies with positive results to be published more often than studies with negative results). They concluded that the included studies may have publication bias due to the nature of the original data. The local areas on the funnel plot may be irregular, but overall there was no significant publication bias.\u003c\/p\u003e\n\n\u003cp\u003eThe risk of bias assessment used the Cochrane criteria and the Newcastle–Ottawa Scale. All included studies scored between 6 and 8 points on the NOS. This classified all included studies as high-quality studies.\u003c\/p\u003e\n\n\u003ch2 id=\"discussion\"\u003eWhat the Results Mean in Context\u003c\/h2\u003e\n\n\u003cp\u003eThis meta-analysis included 11 retrospective studies and 1 randomized controlled trial. It compared the efficacy, survival, and safety of new drug combinations with traditional regimens in 410 newly diagnosed PBL patients. According to the authors, no systematic reviews had previously compared new and traditional therapies for PBL, making this analysis important for clinical practice.\u003c\/p\u003e\n\n\u003cp\u003eThe results showed that compared with traditional regimens, new drug combination regimens significantly improved ORR and PFS in newly diagnosed PBL. Overall survival and adverse reactions were similar between the two groups.\u003c\/p\u003e\n\n\u003cp\u003eThe new drugs studied include bortezomib, rituximab, lenalidomide, hematopoietic stem cell transplantation (autologous and allogeneic), and CAR-T therapy. Among these, \u003cstrong\u003ebortezomib\u003c\/strong\u003e is the most widely used and has shown significant efficacy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhat is PBL?\u003c\/strong\u003e PBL was first discovered in 1997 by Delecluse and colleagues. The exact cause of PBL is currently unclear, but it may be related to viral infection. PBL originates from plasmablasts, which are activated B cells (a type of immune cell). These activated B cells have undergone somatic hypermutation and class switch recombination. Somatic hypermutation and class switch recombination are genetic changes that occur as B cells mature.\u003c\/p\u003e\n\n\u003cp\u003eAccording to relevant literature, the median overall survival of PBL patients is 15 months, and the 3-year overall survival rate is 25%.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSupporting evidence from other studies:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eBarta and colleagues studied 93 cases of HIV-related PBL and found that the EPOCH regimen showed significant advantages in complete remission, PFS, and OS compared to the CHOP regimen.\u003c\/li\u003e\n  \u003cli\u003eCastillo and colleagues used EPOCH combined with bortezomib in 16 newly diagnosed PBL patients. Fifteen patients achieved complete remission and 1 achieved partial remission.\u003c\/li\u003e\n  \u003cli\u003eA multicenter study in the United States showed that consolidation radiotherapy (radiation given after chemotherapy to prevent recurrence) in early PBL can improve outcomes. Chemotherapy combined with radiotherapy showed significantly improved 3-year PFS (85% vs. 65%) and OS (96% vs. 71%) compared to chemotherapy alone.\u003c\/li\u003e\n  \u003cli\u003eCattaneo and colleagues followed 24 newly diagnosed PBL patients for 10 years. Of these, 67% underwent autologous hematopoietic stem cell transplantation (ASCT, using the patient's own stem cells) after first-line therapy. Fifty percent achieved complete remission, 17% achieved partial remission, and the 2-year recurrence rate was 30%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn 2024, Ramirez-Gamero and colleagues reviewed the diagnosis, risk stratification, and treatment of plasma cell lymphoma. They recommended EPOCH with or without bortezomib for PBL patients, with the option of combining local radiotherapy and ASCT for high-risk patients.\u003c\/p\u003e\n\n\u003cp\u003eThis meta-analysis systematically analyzed the data and concluded that chemotherapy regimens combining bortezomib — such as V-EPOCH or V-CHOP — are effective for newly diagnosed PBL. In the study by Fu Weijia and colleagues, 1 case achieved complete remission with combined bortezomib and lenalidomide in first-line treatment. When the disease recurred, 1 case achieved remission again with bortezomib combined with ixazomib.\u003c\/p\u003e\n\n\u003cp\u003eCompared with traditional treatment regimens, bortezomib-based combination chemotherapy significantly improved ORR and PFS in newly diagnosed PBL. This is consistent with previous reports.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, patients who underwent ASCT included 1 patient in the study by Fu Weijia and colleagues, 8 patients in the study by Brian T. Hess and colleagues, 9 patients in the study by Ning Dong and colleagues, and 3 patients in the study by Rehan Jessa and colleagues. Patients who underwent local radiotherapy included 29 patients in the study by Brian T. Hess and colleagues and 10 patients in the study by Ning Dong and colleagues. These additional treatments further improved efficacy.\u003c\/p\u003e\n\n\u003cp\u003eBased on these findings, the authors suggest a treatment regimen of bortezomib combined with EPOCH or CHOP regimens. The regimen should be combined with local radiotherapy as appropriate. The regimen should include ASCT for some high-risk patients. This regimen is a more appropriate option for newly diagnosed PBL.\u003c\/p\u003e\n\n\u003ch2 id=\"future\"\u003eEmerging Treatments and Future Directions\u003c\/h2\u003e\n\n\u003cp\u003eAmong the included studies, only one study compared outcomes of PBL patients who were HIV-positive versus HIV-negative. Other studies included only HIV-positive patients, only HIV-negative patients, or did not provide comparative descriptions. This means the meta-analysis lacks a comparison of efficacy between HIV-positive and HIV-negative patients, which may add bias to the results.\u003c\/p\u003e\n\n\u003cp\u003eAbout 30% of PBL cases express CD30 (a protein found on certain cancer cells). Brentuximab vedotin is a drug that targets CD30. Some researchers have explored targeted therapy for PBL using this drug. Holderness and colleagues reported 1 case of a patient with chronic lymphocytic leukemia (CLL) whose disease partially transformed to PBL. The disease progressed after chemotherapy and radiotherapy. The patient received brentuximab vedotin treatment, and the tumor size significantly reduced.\u003c\/p\u003e\n\n\u003cp\u003eStudies have shown that PD-1 and PD-L1 (proteins that help cancer cells evade the immune system) are also overexpressed and have biological activity in PBL. One case of an early relapsed elderly PBL patient achieved complete remission with pembrolizumab (an immunotherapy drug) plus radiotherapy.\u003c\/p\u003e\n\n\u003cp\u003eCAR-T therapy (a treatment that genetically modifies a patient's own immune cells to attack cancer) for PBL is another research direction. Raghunandan and colleagues reported a case of a young patient who developed PBL after receiving immunotherapy and anti-CD19 CAR-T therapy for acute lymphoblastic leukemia. For PBL, the patient received bortezomib and chemotherapy, followed by allogeneic stem cell transplantation (using donor stem cells). When PBL relapsed, combined chemotherapy regimens containing daratumumab were ineffective. The patient remained in complete remission for 14 months after CAR-T therapy.\u003c\/p\u003e\n\n\u003cp\u003eOther exploration directions for PBL include newly developed drugs for diffuse large B-cell lymphoma (DLBCL) or multiple myeloma. These include venetoclax, selinexor, elotuzumab, CELMODS, and PGRCD5 bispecific antibodies.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis meta-analysis provides important information for patients and their families facing a PBL diagnosis. The key takeaway is that adding newer drugs — especially bortezomib — to standard chemotherapy may improve the chance of responding to treatment and extend the time before the cancer progresses.\u003c\/p\u003e\n\n\u003cp\u003eSpecifically, the study found that:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePatients receiving new drug combinations had a higher objective response rate (70.2% vs. 56.8%)\u003c\/li\u003e\n  \u003cli\u003eProgression-free survival was significantly better with new drug combinations (HR = 2.22, P \u0026lt; 0.001)\u003c\/li\u003e\n  \u003cli\u003eOverall survival was not significantly different between the two groups (HR = 1.81, P = 0.41)\u003c\/li\u003e\n  \u003cli\u003eSerious side effects (grade 3–4) were not significantly different between the two groups (HR = 0.85, P = 0.78)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese findings suggest that bortezomib-based combination regimens, such as V-EPOCH or V-CHOP, may be a better first-line treatment option for newly diagnosed PBL. Adding local radiotherapy when appropriate and considering ASCT for high-risk patients may further improve outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Actionable Advice\u003c\/h2\u003e\n\n\u003cp\u003eBased on the findings of this meta-analysis, the following recommendations may be relevant for patients and their care teams:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss bortezomib-based regimens with your oncologist.\u003c\/strong\u003e The study found that combining bortezomib with EPOCH or CHOP regimens improved response rates and progression-free survival compared with traditional chemotherapy alone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about local radiotherapy.\u003c\/strong\u003e For patients with early-stage PBL, adding radiotherapy after chemotherapy may improve outcomes. One study showed 3-year PFS of 85% with combined treatment versus 65% with chemotherapy alone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider stem cell transplantation if you are high-risk.\u003c\/strong\u003e Autologous hematopoietic stem cell transplantation (ASCT) may be an option for some high-risk patients after first-line therapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBe aware that serious side effects were similar.\u003c\/strong\u003e The study found no significant increase in grade 3–4 adverse events when new drugs were added to traditional treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand the limitations.\u003c\/strong\u003e The small sample size of this study increases the possibility of bias. Discuss the results with your medical team and consider them alongside your individual situation.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Study Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eThe authors identified several important limitations of their study:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmall sample size:\u003c\/strong\u003e The analysis included only 410 patients across 12 studies. This increases the possibility of bias, and the results need to be treated with caution.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMostly retrospective studies:\u003c\/strong\u003e Eleven of the 12 included studies were retrospective (looking back at existing records), with only 1 randomized controlled trial. Retrospective studies are generally considered weaker evidence than prospective randomized trials.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh heterogeneity:\u003c\/strong\u003e The heterogeneity among study results was very high (I² = 95% for ORR), meaning the studies varied considerably in their findings.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLack of HIV comparison:\u003c\/strong\u003e Only one study compared outcomes between HIV-positive and HIV-negative patients. This may add bias to the results.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInsufficient data for finer classification:\u003c\/strong\u003e There was not enough data to analyze newly diagnosed versus relapsed\/refractory patients, different age groups, or different disease stages separately.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo standard treatment exists:\u003c\/strong\u003e Because there is no standard treatment for PBL, comparing different regimens across studies is challenging.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors concluded that further analysis is needed for newly diagnosed, relapsed\/refractory, age, and stage subgroups. The impact of these treatments on the prognosis of PBL patients still needs further exploration.\u003c\/p\u003e\n\n\u003ch2 id=\"conclusion\"\u003eConclusion\u003c\/h2\u003e\n\n\u003cp\u003eThe results of this meta-analysis suggest that using new drugs — especially bortezomib — in the treatment of newly diagnosed PBL may improve patient response rates and survival. The adverse reactions were similar to those of traditional regimens.\u003c\/p\u003e\n\n\u003cp\u003eHowever, the study has certain limitations. All included patients were newly diagnosed with PBL, most studies were retrospective case analyses, and there was not enough data for finer classification. Further analysis is needed for newly diagnosed, relapsed\/refractory, age, and stage subgroups. The impact on the prognosis of PBL patients still needs further exploration.\u003c\/p\u003e\n\n\u003cp\u003eDespite these limitations, this meta-analysis represents the first systematic comparison of new drug combinations versus traditional regimens for PBL. It provides valuable guidance for clinical practice and highlights the potential of bortezomib-based regimens as a more effective treatment option for this rare and aggressive cancer.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is plasmablastic lymphoma (PBL)?\u003c\/h3\u003e\n\u003cp\u003ePBL is a rare and highly aggressive type of non-Hodgkin lymphoma, a cancer of the immune system's white blood cells. It is known for being resistant to standard drug treatments and for poor survival rates. There is currently no standard treatment for PBL, so doctors rely on medium- to high-intensity combination chemotherapy regimens.\u003c\/p\u003e\n\u003ch3\u003eWhat did this analysis find about adding new drugs to chemotherapy for PBL?\u003c\/h3\u003e\n\u003cp\u003eIn 410 newly diagnosed PBL patients across 12 studies, adding newer drugs — especially bortezomib — to standard chemotherapy improved the objective response rate (70.2% vs. 56.8%) and progression-free survival compared with traditional treatment. Overall survival and rates of serious side effects were similar between the two approaches.\u003c\/p\u003e\n\u003ch3\u003eWhat does objective response rate mean in this context?\u003c\/h3\u003e\n\u003cp\u003eObjective response rate is the proportion of patients who achieved complete remission (no detectable cancer) or partial remission (significant reduction in cancer) among all patients eligible for assessment. In this analysis, it was 70.2% with new drug combinations versus 56.8% with traditional treatment.\u003c\/p\u003e\n\u003ch3\u003eDid adding new drugs increase serious side effects?\u003c\/h3\u003e\n\u003cp\u003eAmong 159 patients eligible for safety assessment, there was no significant difference in grade 3–4 adverse events between the two groups (HR 0.85, P = 0.78). Adding new drugs to traditional treatment did not increase the rate of serious side effects. Combination treatment for PBL can cause neurotoxicity, but the new drugs did not increase adverse events.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of this analysis?\u003c\/h3\u003e\n\u003cp\u003eThe analysis included only 410 patients across 12 studies, mostly retrospective, which increases the possibility of bias. Heterogeneity was very high (I² = 95% for objective response rate). Only one study compared HIV-positive and HIV-negative patients, and there was not enough data to analyze subgroups by age, stage, or relapsed\/refractory status.\u003c\/p\u003e\n\u003ch3\u003eWhat treatment options does this analysis suggest for newly diagnosed PBL?\u003c\/h3\u003e\n\u003cp\u003eThe authors suggest bortezomib combined with EPOCH or CHOP regimens (such as V-EPOCH or V-CHOP) as a more appropriate option for newly diagnosed PBL. They also note that local radiotherapy may be added as appropriate, and autologous stem cell transplantation may be considered for some high-risk patients after first-line therapy.\u003c\/p\u003e\n\u003ch3\u003eWhat is the typical outlook for PBL?\u003c\/h3\u003e\n\u003cp\u003eAccording to relevant literature cited in the analysis, the median overall survival of PBL patients is 15 months, and the 3-year overall survival rate is 25%. However, the analysis found that adding newer drugs, especially bortezomib, to standard chemotherapy improved response rates and progression-free survival in newly diagnosed patients.\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient with newly diagnosed plasmablastic lymphoma seek a second opinion?\u003c\/h3\u003e\n\u003cp\u003ePlasmablastic lymphoma has no standard treatment, and this analysis of 410 patients found that adding bortezomib to regimens such as EPOCH or CHOP improved response rates (70.2% vs. 56.8%) and progression-free survival, while overall survival and serious side effects were similar. Because most included studies were retrospective, the sample was small, and heterogeneity was high, a second opinion can help confirm the diagnosis and weigh bortezomib-based regimens, radiotherapy, or stem cell transplantation for high-risk disease. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Meta-analysis of the comparative efficacy and safety of new drugs in combination with chemotherapy in primary plasmoblastic lymphoma.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Bingling Guo, Xi Quan, Zailin Yang, Jieping Li, Yao Liu\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAffiliation:\u003c\/strong\u003e Department of Hematology-Oncology, Chongqing University Cancer Hospital, No. 181 HanYu Road, Chongqing 400030, China\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Clinical and Experimental Medicine (2025) 25:103\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e https:\/\/doi.org\/10.1007\/s10238-025-01636-9\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication dates:\u003c\/strong\u003e Received 25 September 2024; Accepted 14 March 2025; Published online 1 April 2025\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e Natural Science Foundation of Chongqing, China (2023NSCQ-MSX3180); Key Project of Chongqing Technology Innovation and Application Development Special Project (CSTB2024TIAD-KPX0031); and 2025 Chongqing Science and Health Joint Medical Research (2025DBXM002)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePROSPERO registration number:\u003c\/strong\u003e CRD42024578897\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace consultation with a qualified healthcare professional. Patients should discuss their individual treatment options with their medical team.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47807385436316,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0599\/5449\/5644\/files\/ddn-medical-article-new-drugs-plus-chemotherapy-for-plasmablastic-lymphoma-what-a-major-analysis-found-hero.png?v=1792819313","url":"https:\/\/diagnosticdetectives.com\/es\/products\/new-drugs-plus-chemotherapy-for-plasmablastic-lymphoma-what-a-major-analysis-found","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}